[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353423-105":59,"doc-detail-353423-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-novel-therapeutic-monoclonal-antibody-targeting-pzr-demonstrates-potent-antimetastatic-efficacy-in-triple-negative-breast-cancer","A novel therapeutic monoclonal antibody targeting PZR demonstrates potent antimetastatic efficacy in triple-negative breast cancer","","Metastasis drives mortality in triple-negative breast cancer (TNBC), and PZR (MPZL1) is implicated in promoting cancer-cell migration, invasion, and metastatic spread. This study develops a novel anti-PZR monoclonal antibody and humanizes it to test whether PZR targeting can suppress TNBC dissemination. Binding is evaluated by SPR and antibody specificity by western blotting, Co-IP, and FACS, with therapeutic efficacy assessed in vitro and in a TNBC metastasis mouse model.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-novel-therapeutic-monoclonal-antibody-targeting-pzr-demonstrates-potent-antimetastatic-efficacy-in-triple-negative-breast-cancer/353423/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-novel-therapeutic-monoclonal-antibody-targeting-pzr-demonstrates-potent-antimetastatic-efficacy-in-triple-negative-breast-cancer/353423.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does PZR play in triple-negative breast cancer?","Question",{"text":112,"@type":113},"PZR promotes migration, invasion, and metastasis of cancer cells, and the study evaluates whether blocking PZR can inhibit TNBC dissemination.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the anti-PZR monoclonal antibodies developed and assessed?",{"text":117,"@type":113},"Recombinant PZR-ECD protein was used to generate anti-PZR monoclonal antibodies. Binding affinity was evaluated by SPR, and specificity was confirmed by western blotting, Co-IP, and FACS.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic effect did the anti-PZR antibodies show?",{"text":121,"@type":113},"The mouse anti-PZR antibody 12F6 showed high-affinity binding, efficient internalization in PZR-positive TNBC cells, and significant inhibition of migration and metastasis both in vitro and in vivo. The humanized Hu12F6 maintained comparable binding and similarly inhibited migration and metastasis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353423,1790243166,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Chen et al. Journal of Translational Medicine (2026) 24:1094  \n[https://doi.org/10.1186/s12967-026-08469-4](https://doi.org/10.1186/s12967-026-08469-4)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nA novel therapeutic monoclonal antibody targeting PZR demonstrates potent antimetastatic efficacy in triple-negative breast cancer  \nJiayu Chen1†, Jiayi Shao1†, Ju Huang1†, Lingxiao Ye1, Shuya He1, Yaqian Qin2, Zhujun Tian3, Xiaodong Liu3, Licai He 1, Jiawei Cao1, Lan Li3*, Haihua Gu1* and Guang Wu1*  \nAbstract  \nBackground Metastasis is the leading cause of mortality in triple-negative breast cancer (TNBC) . PZR, a member of the immunoglobulin super-family, promotes the migration, invasion, and metastasis of cancer cells. Whether targeting PZR can inhibit TNBC dissemination remains unclear. In this study, we developed a novel anti-PZR monoclonal antibody (mAb) and humanized it to explore its impact onTNBC metastasis.  \nMethods Recombinant PZR-ECD protein was used to generate anti-PZR monoclonal antibodies, whose binding affinity was evaluated by SPR. Their effects on cell migration were assessed via Trans-well assays. Antibody specificity was confirmed by western blotting, Co-IP, and FACS. PZR mediated TNBC cell interactions with the ECM were examined through cell adhesion experiments. The therapeutic efficacy of the PZR antibody was evaluated in aTNBC metastasis mouse model.  \nResults Our findings revealed that the mouse anti-PZR mAb (12F6) exhibited high-affinity binding to the recombinant PZR protein. The 12F6 mAb specifically recognized the native PZR protein expressed by TNBC cells and was efficiently internalized by PZR-positive TNBC cells. Furthermore, 12F6 significantly inhibited the migration and metastasis of PZR-positive TNBC cells in both in vitro and in vivo settings. PZR was found to interact with integrin  \nβ1, promoting the fibronectin-dependent adhesion and FAK activation ofTNBC cells. The humanized 12F6 antibody (Hu12F6) maintained comparable binding affinity to PZR in comparison with the parental 12F6 antibody and effectively inhibited the migration and metastasis of PZR-positive TNBC cells in both in vitro and in vivo experiments.  \n†Jiayu Chen, Jiayi Shao and Ju Huang contributed equally to this work.  \n*Correspondence:  \nLan Li  \n[lanli57@163.com](lanli57@163.com)[ ](lanli57@163.com)Haihua Gu [haihuagu@wmu.edu.cn](haihuagu@wmu.edu.cn)[ ](haihuagu@wmu.edu.cn)Guang Wu [guangwu@wmu.edu.cn](guangwu@wmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nChen et al. Journal of Translational Medicine (2026) 24:1094 Page 2 of 23  \nConclusions The results of our study support a model by which PZR interacting with integrin β1 enhances fibronectin-dependent integrin signaling and biological functions. Hu12F6 by blocking the interaction between PZRand ","cbCaimIIUerP5a7P","https://ap.wps.com/l/cbCaimIIUerP5a7P","pdf",15717719,23,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background","[{\"question\":\"What role does PZR play in triple-negative breast cancer?\",\"answer\":\"PZR promotes migration, invasion, and metastasis of cancer cells, and the study evaluates whether blocking PZR can inhibit TNBC dissemination.\"},{\"question\":\"How were the anti-PZR monoclonal antibodies developed and assessed?\",\"answer\":\"Recombinant PZR-ECD protein was used to generate anti-PZR monoclonal antibodies. Binding affinity was evaluated by SPR, and specificity was confirmed by western blotting, Co-IP, and FACS.\"},{\"question\":\"What therapeutic effect did the anti-PZR antibodies show?\",\"answer\":\"The mouse anti-PZR antibody 12F6 showed high-affinity binding, efficient internalization in PZR-positive TNBC cells, and significant inhibition of migration and metastasis both in vitro and in vivo. The humanized Hu12F6 maintained comparable binding and similarly inhibited migration and metastasis.\"}]","A novel therapeutic monoclonal antibody targeting PZR demonstrates potent antimetastatic efficacy in triple-negative breast cancer | PDF",1790105293,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94d3c5be1dff81809fa7efc54add0821.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d826ee448a2f7e6880d0393cffade651.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c563c5b704d2794093423aefba524037.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d1a14658e30ed148825a90ca525ac0e.webp",980,1306]